secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001178913-25-000247
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion reports preclinical data: SIL-204 systemic admin reduces pancreatic tumor growth ~50%
--------------------------------------------------------------------------------

- Extended-release SIL-204 reduced tumor growth ~50% after 30 days; ~50% of tumors showed complete necrosis in G12D xenografts.
- Subcutaneous SIL-204 inhibited tumor growth in mouse metastatic pancreatic orthotopic models.
- Single systemic dose maintained drug levels in rat plasma and tissues for over 56 days.
- SIL-204 inhibits multiple KRAS mutations: G12D, G12V, G12R, Q61H, and G13D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325000247/0001178913-25-000247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325000247/zk2532610.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-000247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer